SCHEMBL12772007

SCHEMBL12772007

Cc1ccc(P(Cl)Cl)c(CN(Cc2ccccc2)Cc2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.41
MCHR1 Q99705 1/20 0.41
CNR2 P34972 1/20 0.39
ALDH1A1 P00352 5/20 0.37
HTT P42858 2/20 0.37
NPC1 O15118 1/20 0.37
JAK2 O60674 1/20 0.37
RAB9A P51151 1/20 0.37
PAX8 Q06710 1/20 0.37
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.36
TSHR P16473 3/20 0.36
MAPK1 P28482 1/20 0.36
TSPO P30536 1/20 0.35
MIF P14174 3/20 0.35
PTPN1 P18031 1/20 0.35
CD74 P04233 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12772048 0.93 TSHR (0.46) CYP2C19MCHR1CNR2ALDH1A1POLB
SCHEMBL12772009 0.82 CNR2 (0.41) CNR2ALDH1A1TSHRMAPK1PTPN1
SCHEMBL12772012 0.81 HTT (0.37) CNR2HTTMAPK1MIFPTPN1
SCHEMBL12772026 0.81 MIF (0.39) CNR2ALDH1A1TSHRMAPK1MIF
SCHEMBL12772022 0.81 CYP2D6 (0.43) CYP2C19CNR2ALDH1A1RAB9ATSHR
SCHEMBL12771993 0.80 MAPT (0.43) ALDH1A1HTTJAK2POLBMAPT
SCHEMBL12772017 0.79 CYP2C19 (0.35) CYP2C19ALDH1A1HTTNPC1JAK2
SCHEMBL12774300 0.78 CYP2C19 (0.49) CYP2C19MCHR1ALDH1A1HTTNPC1
SCHEMBL12772028 0.78 HSD17B3 (0.37) CYP2C19ALDH1A1HTTNPC1JAK2
SCHEMBL12772045 0.77 KDM4E (0.49) CYP2C19CNR2ALDH1A1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915455-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-03-29 US disclosed
US-7915455-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-03-29 US disclosed
US-20090143620-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED 2009-06-04 US disclosed
US-7482414-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-27 US disclosed
US-7482414-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-27 US disclosed
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-06-14 US disclosed
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex AP1M1, OR10J3, AP2M1 CYP2C19 3142/4885MCHR1 2231/4885CNR2 2126/4885
US-20090143620-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex AP1M1, OR10J3, AP2M1 CYP2C19 3142/4885MCHR1 2231/4885CNR2 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.